European cooperative acute stroke study III: Support for and questions about a truly emerging therapy

Stroke

Volumn 40, Issue 6, 2009, Pages 2262-2263

  Fisher, Marc ^a   Hachinski, Vladimir ^a  

^a University of Massachusetts   (United States)

Author keywords

Acute Rx; Acute stroke; Clinical trials

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DIFFUSION WEIGHTED IMAGING; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; STROKE; TREATMENT RESPONSE; ACUTE DISEASE; BRAIN ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; EUROPE; INTRAVENOUS DRUG ADMINISTRATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RADIOGRAPHY; TREATMENT OUTCOME;

ACUTE DISEASE; CEREBRAL ANGIOGRAPHY; CLINICAL TRIALS AS TOPIC; EUROPE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 66849089770     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.544163     Document Type: Article

References (6)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. The NINDS t-pa Stroke Study Group. Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA stroke trial. Stroke 1997;28:2119-2125.
3. Darby DG, Barber PA, Gerraty RP, Desmond PM, Yang Q, Parsons M, Li T, Tress BM, Davis SM. Pathophysiological topography of acute ischemia by diffusion-weighted and perfusion MRI. Stroke 1999;30:2043-2052.
4. Warach S, for the DIAS 2 Study Group. Clinical benefit of desmoteplase treatment in patients with moderate to severe stroke-further results of the DIAS-2 Study. Presented at the International Stroke Conference; 2008; New Orleans.
5. Ribo M, Molina CA, Rovira A, Quintana M, Delgado P, Montaner J, Grive E, Arenillas JF, Alvarerz-Sabin J. Safety and efficacy of intravenous tissue plasminogen activator in the 3- to 6- hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke 2005;36:602-606.
6. Schellinger PD, Gotz T, Fiehler J, Kohrmann M, Molina CA, Neumann-Haefelin T, Ribo M, Singer OC, Zaro-Weber O, Sobesky J. MRI and CT-based thrombolytic therapy in acute stroke within and beyond established time windows. Stroke 2007;38:2640-2645.